论文部分内容阅读
摘要目的评价对肝脏恶性肿瘤行MR引导下微波消融术的操作成功性、病人安全性以及技术有效性。方法经伦理委员会同意且获取病人的知情同意书。应用1.5 T MR系统对15例病人[(59.8±9.5)岁]的18个肝脏恶性肿瘤(7个肝细胞肝癌,11个转移瘤)行MR引导下微波消融术。平均肿瘤大小为(15.4±7.7)mm(7~37 mm)。操作成功性及消融区直径大小通过消融后MR成像进行测量评价。1个月后进行技术有效性的评价。根据常见不良事件评价标准(CTCAE)对并发症进行分类。平均随访时间为(5.8±2.6)个月(1~10个月)。
Abstract Objective To evaluate the operation success, patient safety and technical effectiveness of microwave ablation under the guidance of MR guided by liver malignancy. Method Approved by Ethics Committee and informed patient consent. Fifteen patients [59.8 ± 9.5] of 18 hepatic malignancies (7 hepatocellular carcinoma and 11 metastatic tumors) underwent MR-guided microwave ablation using the 1.5 T MR system. The mean tumor size was (15.4 ± 7.7) mm (7 to 37 mm). The success rate of operation and the diameter of the ablation zone were evaluated by post-ablation MR imaging. One month later, the technical validity is evaluated. Complications were classified according to Common Criteria for Assessment of Adverse Events (CTCAE). The average follow-up time was (5.8 ± 2.6) months (1-10 months).